Journal Article

Long‐term efficacy of hyperuricaemia treatment in renal transplant patients

Fernando Perez‐Ruiz, Pablo Gomez‐Ullate, Juan J. Amenabar, Sofía Zarraga, Marcelo Calabozo, Ana M. Herrero‐Beites and Joan M. Nolla

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 18, issue 3, pages 603-606
Published in print March 2003 | ISSN: 0931-0509
Published online March 2003 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/18.3.603
Long‐term efficacy of hyperuricaemia treatment in renal transplant patients

Show Summary Details

Preview

Background. Although hyperuricaemia and gout are frequently found in renal transplant recipients, little has been published on the efficacy of urate‐lowering therapy (ULT) in this patient population. We therefore examine the effects of allopurinol and benziodarone therapy in a cohort of renal transplant patients.

Methods. We reviewed files from a cohort of 1328 patients that received renal transplantation. The selection criteria included: functioning allograft, hyperuricaemia for >12 months or gout, ULT lasting at least 1 year and at least two control measurements after the onset of ULT. Patients on azathioprine were treated with benziodarone to avoid azathioprine–allopurinol interactions.

Results. Two‐hundred and seventy‐nine patients fulfilled the criteria for review. They were treated with 289 courses of ULT: 100 with allopurinol (mean dose: 376 mg/day/dl/min of creatinine clearance) and 189 with benziodarone (mean dose: 73 mg/day). The mean follow‐up was 38 months. Both drugs were effective for the control of hyperuricaemia, but benziodarone caused greater reductions in serum uric acid levels, especially when used at mean doses of >75 mg/day. Severe side effects were uncommon, in both the allopurinol and benziodarone groups.

Conclusions. Both allopurinol and benziodarone were effective for the control of hyperuricaemia in renal transplantation. Benziodarone at doses >75 mg/day was more effective than allopurinol in reducing serum uric acid levels and also reduced the risk of azathioprine–allopurinol interactions.

Keywords: allopurinol; benziodarone; hyperuricaemia; renal transplant patients; serum uric acid; urate‐lowering therapy

Journal Article.  2427 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.